Skip to main content
. Author manuscript; available in PMC: 2023 Dec 22.
Published in final edited form as: Cancer Res. 2023 Sep 15;83(18):3013–3025. doi: 10.1158/0008-5472.CAN-23-1252

Figure 4. Protein translation pathways are upregulated in melanomas of APOE2 carrier patients.

Figure 4.

A, Schematic depicting the workflow utilized to analyze transcriptomes of APOE2 and APOE4 carrier melanomas in the TCGA-SKCM cohort (WES, whole exome sequencing). Created with BioRender.com. B, Top ten pathways upregulated in primary tumors of APOE2 carrier patients (n=14) relative to APOE4 carrier patients (n=19) as determined by GSEA and ranked by adjusted p-value (NES, normalized enrichment score; padj, adjusted p-value). C, Top ten pathways upregulated in metastases of APOE2 carrier patients (n=30) relative to APOE4 carrier patients (n=85) as determined by GSEA and ranked by adjusted p-value. D, Model depicting our current understanding of the role of common APOE genetic variants in melanoma progression. The model depicts APOE4 acting as a suppressor of melanoma progression by enhancing anti-tumor immunity as well as repressing angiogenesis and invasion. In contrast, APOE2 is shown as a driver of melanoma progression through its stimulation of protein synthesis via the LRP1 receptor. Created with BioRender.com.